ScholarIQanswers from OpenAlex & ORCID
David L. Porter
ResearcherPublications, citations & collaboration network
David L. Porter is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David L. Porter have?
ScholarIQindexed works
David L. Porter has 44 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David L. Porter have?
ScholarIQcitation count
David L. Porter has 866 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David L. Porter?
ScholarIQh-index
David L. Porter has an h-index of 11 in OpenAlex.
What is the i10-index of David L. Porter?
ScholarIQi10-index
David L. Porter has an i10-index of 11 in OpenAlex.
What is the ORCID of David L. Porter?
ScholarIQorcid
The ORCID for David L. Porter is on the source record.
What is the OpenAlex record for David L. Porter?
ScholarIQopenalex
The OpenAlex for David L. Porter is on the source record.
What are the most-cited papers on David L. Porter?
ScholarIQmost cited works
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
Ginna G. Laport, Bruce L. Levine, Edward A. Stadtmauer, Stephen J. Schuster, Selina M. Luger, Stephan A. Grupp, Nancy Bunin, Frank J. Strobl, Julio Cotte, Zhaohui Zheng, Brian Gregson, Patricia M. Rivers, Robert H. Vonderheide, David Liebowitz, David L. Porter, Carl H. June
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration
Christopher L. Nobles, Scott Sherrill-Mix, J.K. Everett, Shantan Reddy, Joseph A. Fraietta, David L. Porter, Noelle V. Frey, Saar Gill, Stephan A. Grupp, Shannon L. Maude, Donald L. Siegel, Bruce L. Levine, Carl H. June, Simon F. Lacey, J. Joseph Melenhorst, Frederic D. Bushman
The Graft-Versus-Leukemia Effects of Allogeneic Cell Therapy
David L. Porter, Joseph H. Antin
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
Pablo Tebas, Julie K. Jadlowsky, Pamela A. Shaw, Lifeng Tian, Erin Esparza, Andrea Brennan, Su Kyung Kim, Soe Yu Naing, Max W. Richardson, Ashley N. Vogel, Colby R. Maldini, Hong Kong, Xiaojun Liu, Simon F. Lacey, Anya M. Bauer, Felicity Mampe, Lee P. Richman, Gary Lee, Dale Ando, Bruce L. Levine, David L. Porter, Yangbing Zhao, Don L. Siegel, Katharine J. Bar, Carl H. June, James L. Riley
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia
Weimin Kong, Alexander J. Dimitri, Wang Wenliang, In-Young Jung, Christopher J. Ott, Maria Fasolino, Yan Wang, Irina Kulikovskaya, Minnal Gupta, Todd Yoder, Jamie E. DeNizio, J.K. Everett, Erik F. Williams, Jun Xu, John Scholler, Tyler J. Reich, Vijay Bhoj, Kathleen M. Haines, Marcela V. Maus, J. Joseph Melenhorst, Regina M. Young, Julie K. Jadlowsky, Katherine T. Marcucci, James E. Bradner, Bruce L. Levine, David L. Porter, Frederic D. Bushman, Rahul M. Kohli, Carl H. June, Megan M. Davis, Simon F. Lacey, Golnaz Vahedi, Joseph A. Fraietta